Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection

Background: Molecular mimicry targeting neural tissue has been reported after Borrelia burgdorferi(Bb) infection. Herein, we investigate whether antineuronal autoantibodies are increased and whether antibody-mediated signaling of neuronal cells is elevated in a cohort of symptomatic adults with a hi...

Full description

Bibliographic Details
Main Authors: Brian A. Fallon, Barbara Strobino, Sean Reim, Julie Stoner, Madeleine W. Cunningham
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Brain, Behavior, & Immunity - Health
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666354619300158
_version_ 1818664295100055552
author Brian A. Fallon
Barbara Strobino
Sean Reim
Julie Stoner
Madeleine W. Cunningham
author_facet Brian A. Fallon
Barbara Strobino
Sean Reim
Julie Stoner
Madeleine W. Cunningham
author_sort Brian A. Fallon
collection DOAJ
description Background: Molecular mimicry targeting neural tissue has been reported after Borrelia burgdorferi(Bb) infection. Herein, we investigate whether antineuronal autoantibodies are increased and whether antibody-mediated signaling of neuronal cells is elevated in a cohort of symptomatic adults with a history of Lyme Disease (LD). Methods: Participants (n ​= ​179) included 24 with recent Erythema Migrans (EM) without prior LD, 8 with recent EM and prior LD (EM ​+ ​prior LD), 119 with persistent post-treatment LD symptoms (PTLS), and 28 seronegative endemic controls with no prior LD history. Antineuronal immunoglobulin G (IgG) titers were measured by standard ELISA and compared with mean titers of normal age-matched sera against lysoganglioside, tubulin, and dopamine receptors (D1R and D2R). Antibody-mediated signaling of calcium calmodulin dependent protein kinase II (CaMKII) activity in a human neuronal cell line (SK-N-SH) was identified in serum. Results: EM ​+ ​prior LD cases had higher antibody titers than controls for anti-lysoganglioside GM1 (p ​= ​0.002), anti-tubulin (p ​= ​0.03), and anti-D1R (p ​= ​0.02), as well as higher expression in the functional antibody-mediated CaMKII Assay (p ​= ​0.03). The EM cases with no prior history showed no significant differences on any measures. The PTLS cases demonstrated significantly higher titers (p ​= ​0.01) than controls on anti-lysoganglioside GM1, but not for the other measures. Conclusion: The finding of elevated anti-neuronal autoantibodies in our small sample of those with a prior history of Lyme disease but not in those without prior Lyme disease, if replicated in a larger sample, suggests an immune priming effect of repeated infection; the CaMKII activation suggests that antineuronal antibodies have functional significance. The elevation of anti-lysoganglioside antibodies among those with PTLS is of particular interest given the established role of anti-ganglioside antibodies in peripheral and central neurologic diseases. Future prospective studies can determine whether these autoantibodies emerge after Bb infection and whether their emergence coincides with persistent neurologic or neuropsychiatric symptoms.
first_indexed 2024-12-17T05:30:28Z
format Article
id doaj.art-9edd3f2e27ed425ea3b481986510b651
institution Directory Open Access Journal
issn 2666-3546
language English
last_indexed 2024-12-17T05:30:28Z
publishDate 2020-02-01
publisher Elsevier
record_format Article
series Brain, Behavior, & Immunity - Health
spelling doaj.art-9edd3f2e27ed425ea3b481986510b6512022-12-21T22:01:45ZengElsevierBrain, Behavior, & Immunity - Health2666-35462020-02-012100015Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infectionBrian A. Fallon0Barbara Strobino1Sean Reim2Julie Stoner3Madeleine W. Cunningham4Columbia Psychiatry, Columbia University Irving Medical Center, New York, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, USA; Corresponding author. Columbia University, 1051 Riverside Drive, Unit 69, New York, NY, 10032, USA.Columbia Psychiatry, Columbia University Irving Medical Center, New York, USA; New York State Psychiatric Institute, 1051 Riverside Drive, New York, USADepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, USADepartment of Biostatistics, University of Oklahoma Health Sciences Center, Oklahoma City, USADepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, USABackground: Molecular mimicry targeting neural tissue has been reported after Borrelia burgdorferi(Bb) infection. Herein, we investigate whether antineuronal autoantibodies are increased and whether antibody-mediated signaling of neuronal cells is elevated in a cohort of symptomatic adults with a history of Lyme Disease (LD). Methods: Participants (n ​= ​179) included 24 with recent Erythema Migrans (EM) without prior LD, 8 with recent EM and prior LD (EM ​+ ​prior LD), 119 with persistent post-treatment LD symptoms (PTLS), and 28 seronegative endemic controls with no prior LD history. Antineuronal immunoglobulin G (IgG) titers were measured by standard ELISA and compared with mean titers of normal age-matched sera against lysoganglioside, tubulin, and dopamine receptors (D1R and D2R). Antibody-mediated signaling of calcium calmodulin dependent protein kinase II (CaMKII) activity in a human neuronal cell line (SK-N-SH) was identified in serum. Results: EM ​+ ​prior LD cases had higher antibody titers than controls for anti-lysoganglioside GM1 (p ​= ​0.002), anti-tubulin (p ​= ​0.03), and anti-D1R (p ​= ​0.02), as well as higher expression in the functional antibody-mediated CaMKII Assay (p ​= ​0.03). The EM cases with no prior history showed no significant differences on any measures. The PTLS cases demonstrated significantly higher titers (p ​= ​0.01) than controls on anti-lysoganglioside GM1, but not for the other measures. Conclusion: The finding of elevated anti-neuronal autoantibodies in our small sample of those with a prior history of Lyme disease but not in those without prior Lyme disease, if replicated in a larger sample, suggests an immune priming effect of repeated infection; the CaMKII activation suggests that antineuronal antibodies have functional significance. The elevation of anti-lysoganglioside antibodies among those with PTLS is of particular interest given the established role of anti-ganglioside antibodies in peripheral and central neurologic diseases. Future prospective studies can determine whether these autoantibodies emerge after Bb infection and whether their emergence coincides with persistent neurologic or neuropsychiatric symptoms.http://www.sciencedirect.com/science/article/pii/S2666354619300158Lyme diseaseAntineuronal antibodiesLysogangliosideCaMKinase II
spellingShingle Brian A. Fallon
Barbara Strobino
Sean Reim
Julie Stoner
Madeleine W. Cunningham
Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
Brain, Behavior, & Immunity - Health
Lyme disease
Antineuronal antibodies
Lysoganglioside
CaMKinase II
title Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
title_full Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
title_fullStr Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
title_full_unstemmed Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
title_short Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection
title_sort anti lysoganglioside and other anti neuronal autoantibodies in post treatment lyme disease and erythema migrans after repeat infection
topic Lyme disease
Antineuronal antibodies
Lysoganglioside
CaMKinase II
url http://www.sciencedirect.com/science/article/pii/S2666354619300158
work_keys_str_mv AT brianafallon antilysogangliosideandotherantineuronalautoantibodiesinposttreatmentlymediseaseanderythemamigransafterrepeatinfection
AT barbarastrobino antilysogangliosideandotherantineuronalautoantibodiesinposttreatmentlymediseaseanderythemamigransafterrepeatinfection
AT seanreim antilysogangliosideandotherantineuronalautoantibodiesinposttreatmentlymediseaseanderythemamigransafterrepeatinfection
AT juliestoner antilysogangliosideandotherantineuronalautoantibodiesinposttreatmentlymediseaseanderythemamigransafterrepeatinfection
AT madeleinewcunningham antilysogangliosideandotherantineuronalautoantibodiesinposttreatmentlymediseaseanderythemamigransafterrepeatinfection